Navigation Links
ISTA Pharmaceuticals Announces Preliminary Results of T-Pred Studies
Date:9/8/2009

IRVINE, Calif., Sept. 8 /PRNewswire-FirstCall/ -- ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced preliminary results from two recently completed studies on its investigational ophthalmic product, T-Pred(TM) (prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension). The Company is developing T-Pred as a treatment for inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial ocular infection exists, or there is a risk of bacterial infection.

In the first study, ISTA evaluated the antimicrobial equivalence between T-Pred and a tobramycin-containing reference product. In vitro tests were conducted to compare the kill rate of T-Pred with the kill rate of the reference product for each of the micro-organisms listed in the reference product's package insert as well as additional micro-organisms specified by the Food and Drug Administration (FDA). ISTA successfully demonstrated the antimicrobial bioequivalence of T-Pred to the reference product in each of the 26 required tests.

The second study was a Phase 3 clinical study designed to determine the bioequivalence of prednisolone concentrations between T-Pred and a reference product containing prednisolone acetate 1.0%. The multi-center, randomized, double-masked study enrolled 172 patients undergoing bilateral cataract removal. Patients served as their own internal control in this study, receiving one drop of either T-Pred or the prednisolone reference product prior to cataract extraction. Aqueous humor sampling was performed at one of four assigned time points. In order to demonstrate the bioequivalence of the two products, the ratio of calculated prednisolone values in aqueous humor needed to fall between 80% and 125%, with a 90% confidence interval for the rat
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
2. Vion Pharmaceuticals Announces Results of the Oncologic Drugs Advisory Committee Meeting for Onrigin(TM)
3. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
4. ISTA Pharmaceuticals Announces Positive Preliminary Phase 3 Clinical Results to Support sNDA Filing for Once-Daily Xibrom(TM) 0.09%
5. NovaBay Pharmaceuticals to Present New Data on Lead Anti-Infective Compound at the 2009 ICAAC Annual Meeting
6. Impax Pharmaceuticals Selects OmniComm Systems to Provide eClinical Solutions for International Phase III Study in Parkinsons Disease
7. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
8. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
9. Eiger BioPharmaceuticals Announces Initiation of CLEAN-1 HCV Phase 1b Trial
10. Access Pharmaceuticals Provides Update on ProLindac Clinical Development Program
11. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... NEW YORK , Dec. 22, 2014 /PRNewswire/ ... developing novel therapies for the treatment of chronic ... subjects has been dosed in a pharmacokinetic and ... receptor antagonist for neuropathic pain. Racemic ... treatment of various pain states and substitution therapy ...
(Date:12/19/2014)... 2014 TODAY, AEGATE, the leader ... announced the appointment of Peter Fox as ... Channels and Partner Officer. Peter has served ... its acquisition by Oracle in 2011. Prior ... Geneva and subsequently Convergys, a world renowned ...
(Date:12/19/2014)... 2014  Advanced Medical Isotope Corporation ("AMIC") (OTCQB:  ... in the development of brachytherapy devices and medical ... that a Life Sciences Discovery Fund (LSDF) Proof ... AMIC is the commercialization partner.  The award was ... proposal titled "Optimized Injectable Radiogels for High-dose Therapy ...
Breaking Medicine Technology:Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 2Relmada Therapeutics Doses First Cohort of Subjects in Human Clinical Trial of d-Methadone 3Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 2Advanced Medical Isotope Corporation Awarded LSDF Grant As Commercialization Partner 3
... Schering-Plough Corporation,(NYSE: SGP ) today reported that ... Phase II study of boceprevir, its investigational oral ... chronic,hepatitis C virus (HCV) genotype 1 were presented ... for the Study of the Liver (EASL). The,ongoing ...
... Into New Promising Drugs to Combat Hepatitis ... C ... Stem Cells of Potential Benefit in Liver Transplantation, ... At today,s sessions of the 43rd Annual Meeting of the European,Association for the ...
Cached Medicine Technology:Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 2Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 3Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 4Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 5Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 6Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 7Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 8Interim Results from Boceprevir Phase II Study in Genotype 1 Treatment-Naive Hepatitis C Patients Presented At EASL 9Basic Science Discoveries Yield Progress in Hepatology 2Basic Science Discoveries Yield Progress in Hepatology 3Basic Science Discoveries Yield Progress in Hepatology 4
(Date:12/22/2014)... 22, 2014 Pasadena sleep apnea ... for sleep apnea. Drowsy drivers are 15 times more ... are well-rested, and some experts believe that sleep-deprived drivers ... intoxicated drivers. Unfortunately, millions of Americans may be sleep-deprived ... of Sleep Medicine, about 18 million Americans have sleep ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley ... to provide logistics and support for one of Dallas’ ... a long history of giving back to the community in ... year's Toy Drive were Whataburger® and 99.5 The Wolf. , ... holidays. Providing gifts to children who would otherwise not receive ...
(Date:12/22/2014)... A substantial percentage of patients ... (CT) to evaluate abnormal findings on outpatient chest ... to a new study published online in the ... show that radiologist recommendations for additional imaging (RAIs) ... care. , RAIs, which have grown 200 percent ...
(Date:12/21/2014)... In this report, the global ... source, product, and application. The market, by power ... instruments. By product, the market covers the handpieces; ... handpieces market is further subdivided into drills, saws, ... instruments, shavers, wire/pin drivers, and others. Moreover, the ...
(Date:12/21/2014)... Hills, Ca (PRWEB) December 21, 2014 ... Khanna was a guest at the Aspen Helicopters holiday ... kids and a Santa with sleigh, flown by an ... helicopter appeared invisible; only Santa with sleigh was visible.(please ... during day and night. Dr.Khanna has helped many pilots ...
Breaking Medicine News(10 mins):Health News:Pasadena Dentist, Dr. Marine Martirosyan, Now Offers Consultations for Sleep Apnea 2Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 2Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 3Health News:Global Powered Surgical Instruments Market Hit to $2.1 billion by 2019 - New Research Report by MarketsandMarkets 4
... from Spain to Lithuania, thirteen research institutes from eleven European ... was Professor Dr Jeroen Buters of TUM,s Chair of Molecular ... mission was to study the three main causes of hay ... trees, grass and olive plants. Sufferers develop allergic symptoms when ...
... Rochelle, NY, May 21, 2012Currently more than 10% of ... that target pregnancy, infancy, and toddlers are urgently needed ... as proposed in an article in Childhood Obesity ... publishers. The article is available free online ahead of ...
... - Environmental scientists at Harvard have discovered that the ... by both atmospheric forces and the flow of circumpolar ... Ocean. While the atmospheric source was previously recognized, ... comes from the rivers. The revelation implies that ...
... mei 2012 - VIB researcher Diether Lambrechts, associated with ... predict which patients will benefit more from treatment with ... important step towards personalized medicine and patient-tailored use of ... KU Leuven) said "in two large clinical studies with ...
... limits sexual activity is common among older patients with ... "We compared measures of well-being, depression and sexual function ... both of which are associated with dypnea during exertion," ... Hospital in Denmark. "A significantly higher percentage of COPD ...
... more intensely than walking without poles. The research ... , 19-22 May, in Belgrade, Serbia. The Congress is ... of the European Society of Cardiology., Aerobic ... life and reduces heart failure related hospitalisations. However, many ...
Cached Medicine News:Health News:Some pollens are much more aggressive than others 2Health News:A systems approach to preventing obesity in early life 2Health News:Toxic mercury, accumulating in the Arctic, springs from a hidden source 2Health News:Toxic mercury, accumulating in the Arctic, springs from a hidden source 3Health News:Toxic mercury, accumulating in the Arctic, springs from a hidden source 4Health News:Biomarker predicts response to cancer treatment 2Health News:Troublesome dyspnea during sexual activity is common in COPD patients 2Health News:Nordic walking improves health of heart failure patients 2
The Storz Protege is an anterior segment unit only....
The CV-12000 provides the surgeon with all the options to perform today's newest techniques....
Phaco-emulsification systems CV series...
The unprecedented power, flexibility and versatility of the Series 20000 Legacy have made it the world's leading phacoemulsifier....
Medicine Products: